Diagnostic and Therapeutic Challenges in Lemierre Syndrome: A Case Report Using Metagenomic Next Generation Sequencing
Qi Qi,Jun Yang,Linhui Yang,Huohuan Tian,Chun Wan,Dan Liu
DOI: https://doi.org/10.2147/idr.s455994
2024-04-30
Infection and Drug Resistance
Abstract:Qi Qi, &ast Jun Yang, &ast Linhui Yang, Huohuan Tian, Chun Wan, Dan Liu Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Dan Liu; Chun Wan, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China, Email ; Lemierre syndrome (LS) is a rare and life-threatening condition predominantly caused by Fusobacterium necrophorum. Currently, there are no standardized clinical guidelines for LS management. Here, we describe the case of a 40-year-old male with fever, productive cough, and dyspnea but no sore throat. Diagnostic radiological examinations revealed multiple pulmonary cavitary nodules and an internal jugular vein occlusion. Metagenomic Next-Generation Sequencing (mNGS) of the alveolar lavage fluid identified Fusobacterium necrophorum, thereby confirming the diagnosis of LS. Intriguingly, the patient exhibited a delayed clinical response despite receiving the appropriate antibiotic. After integrating tigecycline into the treatment to address potential co-infecting bacteria, we observed a marked improvement in his clinical symptoms. Subsequent follow-up over 12 weeks post-discharge revealed complete alleviation of symptoms, and a chest CT scan showed marked regression of the lung lesions. Keywords: Lemierre syndrome, Fusobacterium necrophorum, septic thrombophlebitis, antibiotic therapy, anticoagulation Lemierre syndrome (LS), originally described by Prof. Lemierre in 1936, is characterized by septic thrombophlebitis, predominantly affecting the internal jugular vein, which subsequently embolizes and causes peripheral septic lesions such as metastatic lung abscesses. 1 The predominant causative agent of LS is Fusobacterium necrophorum, a gram-negative anaerobic bacillus frequently located in the oropharyngeal region. 2 Predominantly affecting young and healthy individuals, LS has an annual incidence of 14.4 cases per million among adolescents aged 15–24. 3,4 Notably, it has been hypothesized that the incidence of LS may have risen over recent decades possibly owing to antibiotic resistance, increased syndrome awareness, and fewer tonsillectomies. 5 However, not all LS cases present typical clinical symptoms, which can result in misdiagnoses. Patients with LS have a higher risk of thromboembolic complications and mortality. 6 Timely recognition and standard antibiotic regimens are vital for improving patient prognosis. The primary treatment modalities for LS comprise antibiotic and anticoagulant therapies. We detail a case where a prompt resolution of clinical symptoms was challenging even with adherence to a standardized antibiotic regimen. A 40-year-old male was admitted to the emergency room with an 8-day history of fever, productive cough, and dyspnea but without a sore throat. He reported no pharyngeal pain prior to admission and had not undergone any recent dental procedures. Physical examination revealed bilateral coarse breath sounds with scattered rales and edema in the lower extremities. The oropharyngeal examination was unremarkable. Laboratory analysis showed a white cell count of 20.31×10^9 cells/L with 87.7% neutrophils. Procalcitonin was 44.91 ng/mL, C-reactive protein was 54.40 mg/L, interleukin 6 was 117.20 pg/mL, thrombocytopenia (platelet count of 17×10^9/L) and D-Dimer concentration was 9.12mg/L. Immediate radiologic assessment included a chest CT revealing multiple cavitated nodules and moderate pleural effusion (Figure 1A). Empirical treatment with meropenem and moxifloxacin was initiated, alongside chest drainage and admission to the hospital ward for further management. Figure 1 ( A ) Chest CT upon admission reveals scattered nodules and encapsulated pleural effusion in both lungs. ( B ) After a 10-day course of oral ceftriaxone and metronidazole, chest CT indicates a partial reduction of the pulmonary lesions. ( C ) Subsequent chest CT at 12 weeks post-antibiotic treatment, demonstrating significant and sustained regression of pulmonary lesions. Three days later, the blood cultures yielded growth of both gram-negative rods and gram-positive cocci. This prompted an adjustment in the antibiotic regimen, transitioning to vancomycin and imipenem. The patient's lower extremity edema persisted asymmetrically, despite no significant findings on lower extremity venous ultrasonography. Laboratory tests showed an increased platelet count of 452 × 10^9/L and a further elevated D-dimer concentration of 12.3 mg/L. Given these laboratory changes, prophylactic anticoagulation with enoxaparin (4000 AXaIU/d -Abstract Truncated-
pharmacology & pharmacy,infectious diseases